Ipratropium Bromide Nasal Solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis
Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US)
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term
The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Cyanocobalamin Nasal Spray (RLD Nascobal) had estimated annual sales of USD 69 million in the U.S. (IQVIA MAT Mar 2023)
The partnership will commercialize four nasal sprays with a combined Global IQVIA market size in excess of $400m
APF Futurity is made from polyolefin materials with no metal parts or recycling disruptors
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
Subscribe To Our Newsletter & Stay Updated
